Tim's career spans 30+ years in large-cap pharma (Merck and Boehringer Mannheim), large-cap biotech (Genentech), start-up biotech (ILEX and DirectGene) and consulting. Tim has experience building the links and infrastructure necessary to bring innovative biotech products to market through his thorough understanding of pharmaceutical company needs and capabilities, including experience marketing new products, negotiating international product licensing agreements, building sales and marketing organizations and building a successful start-up company from scratch (i.e., ILEX Oncology where he was one of the first three employees). Tim has played key roles in the development and launch of such products as Merck's first recombinant vaccine, Genentech's recombinant human growth hormone (rHGH) and recombinant tissue plasminogen activator (rTPA), and ILEX's humanized monoclonal antibody, CAMPATH. Prior to joining SMi, Tim negotiated numerous product deals and alliances including ILEX's agreement giving Schering AG worldwide distribution rights to CAMPATH in return for $30.0 million in fees and milestones, 60% of the profit in the U.S. and a royalty comparable to 60% profit in the rest of the territory (The Pink Sheet, 08/30/99, p. 21).